Gender Reassignment Surgery in India and UAE | Complete Patient Guide

• ELIGIBILITY — GENERAL CRITERIA (WPATH SOC8 Aligned):

• Confirmed diagnosis of gender dysphoria or gender incongruence by a qualified mental health professional (DSM-5-TR or ICD-11 criteria)

• Minimum age: 18 years for genital surgery (some centers accept 16–17 with parental consent and dual MHP sign-off for non-genital procedures)

• Minimum 12 months of consistent, documented hormone therapy appropriate to affirmed gender (testosterone for FTM; estrogen ± anti-androgen for MTF), unless medically contraindicated

• Real-life experience in affirmed gender role (duration as clinically determined by treating team)

• Two independent letters of support from qualified mental health professionals for genital surgery

• Capacity to provide fully informed consent

• BMI ideally <30 for reconstructive genital procedures (BMI >35 significantly increases flap failure risk in phalloplasty)

• REQUIRED PRE-OPERATIVE DIAGNOSTICS & INVESTIGATIONS:

• Comprehensive metabolic panel (CMP), CBC with differential, coagulation profile (PT/INR/aPTT)

• Hormone panel: serum estradiol, testosterone, LH, FSH, prolactin (to confirm therapeutic hormone levels)

• HIV, Hepatitis B surface antigen, Hepatitis C antibody, syphilis serology (VDRL/RPR)

• Thyroid function tests (TSH, Free T4) — relevant given long-term hormone use

• Pelvic ultrasound (FTM patients undergoing hysterectomy/oophorectomy)

• Scrotal and penile tissue assessment (MTF: to confirm adequate skin for penile inversion; prior circumcision noted)

• Urological evaluation: uroflowmetry baseline (relevant for MTF vaginoplasty and FTM urethral lengthening)

• Psychological/psychiatric clearance letter(s)

• Anesthesiology fitness assessment including ECG, chest X-ray, and pulmonary function in patients >40 or with comorbidities

• Allen's test and Doppler vascular assessment of forearm vasculature (mandatory for RFFF phalloplasty candidates)

• CT angiography of donor site vasculature for ALT flap phalloplasty

• CONTRAINDICATIONS (ABSOLUTE):

• Active, untreated or unstable psychiatric illness (psychosis, active suicidal ideation without safety plan) — surgery deferred, not denied

• Active thromboembolic disease or hypercoagulable state not medically optimized

• Severe, uncontrolled cardiovascular disease or ASA Class IV anesthetic risk

• Active or poorly controlled diabetes (HbA1c >8.0% — increases wound complication and flap failure risk substantially)

• Active smoker within 4–6 weeks of surgery (nicotine causes microvascular vasoconstriction; critical in free flap phalloplasty)

• HIV with detectable viral load or CD4 <200 cells/µL (increased surgical infection risk)

• Significant hepatic insufficiency (Child-Pugh Class B/C)

• RELATIVE CONTRAINDICATIONS / FACTORS REQUIRING OPTIMIZATION:

• Obesity (BMI 30–35): requires pre-surgical weight reduction program

• Prior pelvic or perineal surgery (impacts tissue availability and vascular anatomy)

• Prior scrotal surgery or extensive scarring (MTF)

• History of keloid formation (relevant for chest surgery and donor site scars)

• Insufficient penile/scrotal skin for penile inversion vaginoplasty (surgeon may recommend staged scrotal skin grafting or intestinal vaginoplasty)

MALE-TO-FEMALE (MTF) PROCEDURES:

1. PENILE INVERSION VAGINOPLASTY (PIV) — Global Standard Technique

The penile skin is inverted to form the neovaginal canal (8–12 cm depth, 3–4 cm diameter). The glans penis is sculpted into a sensate neoclitoris, preserving the dorsal neurovascular bundle to maintain erogenous sensation. Labia majora are constructed from scrotal skin; labia minora from penile shaft or preputial skin. A perineal dissection creates the neovaginal cavity between the rectum and urethra, requiring meticulous tissue plane identification to prevent rectal injury. The urethra is shortened and repositioned. This technique is the most widely performed globally, with high-volume centers reporting neovaginal depth retention of 10–12 cm at 12 months with consistent dilation compliance.

2. SIGMOID COLON VAGINOPLASTY (Intestinal/Bowel Vaginoplasty)

Indicated when penile/scrotal tissue is insufficient (e.g., post-circumcision with minimal penile shaft skin, revision after prior failed PIV, or pediatric-onset hormone therapy with limited genital tissue development). A segment of sigmoid colon (~15 cm) is mobilized laparoscopically and anastomosed to the perineum to form a self-lubricating neovaginal canal. Laparoscopic-assisted approach reduces abdominal wall morbidity. Provides natural mucosal lubrication, eliminating the need for artificial lubricants during intercourse. Requires bowel preparation and carries additional risks of mucus discharge, bowel anastomotic leak, and diversion colitis.

3. ZERO-DEPTH VAGINOPLASTY / VULVOPLASTY

For patients who do not desire sexual intercourse or cannot commit to post-operative dilation. Creates cosmetically natural external female genitalia (labia majora, labia minora, clitoral hood, clitoris, urethral meatus) without a vaginal canal. Shorter operative time (~2–3 hours vs. 4–6 hours for PIV), faster recovery, and lower complication profile. Increasingly chosen by asexual or non-binary patients.

4. ORCHIECTOMY (Standalone)

Bilateral removal of testes. Eliminates endogenous testosterone production, allowing reduction or elimination of anti-androgen medication. Often the first surgical step for patients not yet ready for vaginoplasty. Short procedure (60–90 minutes), day surgery or overnight stay.

5. ANCILLARY MTF PROCEDURES:

• Breast Augmentation: Silicone or cohesive gel implants (dual-plane or subglandular); frequently combined with hormone-induced breast development assessment

• Facial Feminization Surgery (FFS): Forehead contouring/brow bossing reduction, hairline advancement, rhinoplasty, lip lift, mandible contouring, genioplasty, tracheal shave (chondrolaryngoplasty) — often performed as a combined case under one anesthetic

• Vocal Cord Surgery (Glottoplasty / Cricothyroid Approximation): Raises fundamental voice frequency

FEMALE-TO-MALE (FTM) PROCEDURES:

1. METOIDIOPLASTY

Utilizes the testosterone-enlarged clitoris (typically 4–7 cm after ≥2 years of T therapy) as the neophallic structure. The suspensory ligament is released to advance the neophallus, and urethral lengthening using vaginal mucosal and labial flaps allows for standing urination. Scrotoplasty is performed using labia majora tissue, with testicular implants placed at a second stage. Advantages: single-stage, no donor site scar, preserves native erogenous sensation. Limitation: smaller neophallic size (typically insufficient for penetrative intercourse).

2. RADIAL FOREARM FREE FLAP (RFFF) PHALLOPLASTY — The Workhorse Technique

A fasciocutaneous flap from the non-dominant forearm is harvested with the radial artery and venae comitantes. The flap is tubed to create a neophallic shaft with an integrated urethral tube (tube-within-a-tube design). Microsurgical anastomosis connects the flap vasculature to the femoral or inferior epigastric vessels. Urethral lengthening bridges the native urethra to the neophallic urethra. Provides adequate girth and length for penetrative intercourse (with penile implant at Stage 2). Preserves glans sensation via dorsal clitoral nerve coaptation. Donor site: skin-grafted forearm scar (cosmetically significant; primary consideration for patient counseling).

3. ANTEROLATERAL THIGH (ALT) FLAP PHALLOPLASTY

Alternative free flap using anterolateral thigh perforator flap — larger tissue volume, more concealed donor site scar, preferred in patients with darker skin tones or concerns about forearm scarring. Technically more demanding due to perforator variability; requires pre-operative CT angiography to map perforator anatomy. Provides excellent girth; urethroplasty integrated or staged.

4. MUSCULOCUTANEOUS LATISSIMUS DORSI (MLD) FLAP PHALLOPLASTY

Used in revision cases or when forearm and thigh donor sites are unsuitable. Provides a well-vascularized, bulky flap; requires positional changes during surgery.

5. PENILE PROSTHESIS IMPLANTATION (Stage 2 / 3 of Phalloplasty)

Erectile function after phalloplasty requires implantation of a penile prosthesis: inflatable 3-piece hydraulic devices (AMS 700 series, Coloplast Titan) or malleable semi-rigid rods. Performed as a second-stage procedure (minimum 12 months after phalloplasty to allow neourethral maturation and flap consolidation). Device mechanical reliability at 5 years: ~80–85%.

6. HYSTERECTOMY AND BILATERAL SALPINGO-OOPHORECTOMY (BSO)

Total laparoscopic hysterectomy (TLH) with BSO is performed for FTM patients wishing to eliminate menstruation, estrogen production, and gynecological cancer risk. Performed laparoscopically in the majority of cases (minimally invasive; 2–3 port technique). Can be combined with metoidioplasty or as a standalone procedure.

7. CHEST MASCULINIZATION (BILATERAL MASTECTOMY / TOP SURGERY)

The most commonly requested FTM procedure. Technique selection depends on breast volume and skin laxity:

• Double Incision / Bilateral Mastectomy with Free Nipple Grafts: For larger chest (B-cup and above); horizontal chest scars with repositioned nipple-areola complexes

• Periareolar / Concentric Mastopexy Technique: For smaller chest (A-cup); circumareolar scar, preserves native nipple sensation

• Keyhole/Endoscopic Technique: Minimal skin, small areolar incision; for very small, non-ptotic chests

TECHNOLOGY & INNOVATION IN GRS:

• Robotic-Assisted Laparoscopic Hysterectomy (da Vinci Surgical System): Available at select centers in both India and UAE; reduces blood loss, improves precision in pelvic dissection

• 3D Surgical Planning Software: Used in FFS and phalloplasty for pre-operative simulation

• Perforator Doppler Mapping and CT Angiography: Standard pre-operative workup for ALT flap phalloplasty

• Regenerative Scaffolding for Neourethra: Investigational use of acellular dermal matrix (ADM) for urethral reconstruction in complex revision phalloplasty

• Minimally Invasive Bowel Preparation Protocols: Enhanced Recovery After Surgery (ERAS) pathways applied at JCI-accredited centers reduce hospital stay and post-operative ileus rates

PHASE 1 — PRE-TRAVEL PREPARATION (6–12 Weeks Before Surgery)

• GAF Healthcare case manager conducts detailed intake: reviews medical records, surgical goals, psychiatric letters, and hormone therapy history

• Surgical team conducts virtual pre-operative consultation (video call); surgeon reviews imaging, tissue assessment, and confirms surgical plan

• Pre-operative lab package issued; patient completes investigations locally and uploads results

• Hormone therapy optimization confirmed: estradiol or testosterone at therapeutic levels; anti-androgens (spironolactone or bicalutamide) reviewed

• Smoking cessation mandatory ≥4 weeks prior (critical for flap surgery)

• VTE prophylaxis counseling: low-dose aspirin or LMWH protocol discussed with treating physician

• Medical visa application initiated for India (e-Medical Visa); UAE entry visa or visa-on-arrival arranged as applicable

• Accommodation for patient and attendant confirmed near the surgical center

PHASE 2 — ARRIVAL & PRE-OPERATIVE ASSESSMENT (Days 1–3 in Country)

• Day 1: Airport pickup by GAF Healthcare coordinator; hotel check-in; rest

• Day 2: In-person surgical consultation; meet surgeon, anesthesiologist, and nursing team; final tissue assessment and surgical marking; informed consent process

• Day 3: Final pre-operative blood work, ECG, chest X-ray, anesthesiology clearance; nil-by-mouth instructions issued; bowel preparation if sigmoid vaginoplasty planned

PHASE 3 — SURGICAL PROCEDURE

• MTF PENILE INVERSION VAGINOPLASTY: Operative time 4–6 hours under general anesthesia; epidural or spinal analgesia supplement common; intraoperative rectal probe monitoring to prevent rectal perforation; vaginal packing placed at end of case

• FTM RFFF PHALLOPLASTY: Operative time 6–10 hours (two surgical teams operating simultaneously — flap harvest and recipient site preparation); microsurgical anastomosis under operating microscope; flap perfusion confirmed intraoperatively by Doppler

• FTM METOIDIOPLASTY: Operative time 3–5 hours; urethral lengthening and scrotoplasty included

• CHEST MASCULINIZATION (TOP SURGERY): Operative time 2–3 hours; drains placed bilaterally

• Immediate post-operative monitoring in ICU or High Dependency Unit (HDU) for major procedures

PHASE 4 — IMMEDIATE POST-OPERATIVE HOSPITAL STAY (Days 1–7/10)

• Day 1 post-op: Bedrest; IV analgesia (multimodal: opioid-sparing NSAID + acetaminophen + regional block where applicable); IV antibiotics; VTE prophylaxis (LMWH — enoxaparin); urinary catheter in situ

• Days 2–3: Progressive mobilization with physiotherapy; transition to oral analgesia; diet advancement per ERAS protocol

• MTF vaginoplasty — Day 5 or 6: Vaginal packing removed; first vaginal dilation performed by nursing team under supervision; patient taught dilation technique (initial protocol: 30–45 minutes, 3–4 times daily)

• FTM phalloplasty — Flap monitoring: hourly Doppler checks for 48–72 hours; skin paddle color, turgor, and capillary refill assessed; suprapubic catheter placed if urethral lengthening performed

• Chest surgery drains removed when output <30 mL/24 hours (typically Day 2–4)

• Discharge criteria: afebrile, oral analgesia adequate, wound stable, patient independent with dilation (MTF) or catheter care (FTM)

PHASE 5 — RECOVERY IN COUNTRY (Weeks 1–6/8 Post-Op)

• Patient stays in serviced accommodation near the hospital; daily or alternate-day wound checks arranged by GAF Healthcare

• MTF VAGINOPLASTY DILATION SCHEDULE: Weeks 1–6: 3–4 sessions/day, 30 minutes each using graduated dilators (Hegar sizes 25–35 mm); this is the most critical determinant of long-term vaginal depth maintenance — non-compliance is the primary cause of stenosis

• FTM PATIENTS: Suprapubic catheter typically remains 4–6 weeks until neourethra heals (confirmed by voiding cystourethrogram before catheter removal)

• Wound care: Silicone gel strips for scar management initiated at Week 3–4

• Hormone therapy resumed: estrogen restarted at lowest effective dose (VTE risk period); testosterone typically continued throughout

• Week 4 review: Surgeon assesses healing; imaging if urethral complications suspected

• FIT-TO-FLY MILESTONE: MTF vaginoplasty/vulvoplasty/orchiectomy — 4–6 weeks; FTM metoidioplasty — 5–6 weeks; FTM phalloplasty — 6–8 weeks (catheter must be removed and voiding confirmed before travel)

PHASE 6 — LONG-TERM FOLLOW-UP (Months 3, 6, 12 Post-Op)

• Virtual follow-up consultations with surgical team coordinated by GAF Healthcare at 6 weeks, 3 months, 6 months, and 12 months

• MTF: Dilation frequency tapers to once daily by Month 3; once weekly for life thereafter (or as per surgeon guidance based on vaginal depth maintenance)

• FTM phalloplasty Stage 2 (penile prosthesis): Planned at minimum 12 months post-phalloplasty; patient returns for second visit

• Gynecological oncology surveillance for MTF patients (prostate cancer risk remains with retained prostate)

• Ongoing endocrinology follow-up: Annual hormone panel, bone density (DEXA) scan, cardiovascular risk assessment